Bionano Genomics (BNGO) Stock Price, News & Analysis

Company Overview

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $3.80 to $4.08
• 50-Day Range: $2.91 to $4.13
• 52-Week Range: $2.68 to $32.79
• Volume: 313,883 shs
• Average Volume: 125,193 shs
• Market Capitalization: $13.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.50
• Consensus Rating: Hold

Bionano Genomics Stock Analysis - MarketRank™

Bionano Genomics scored higher than 42% of companies evaluated by MarketBeat, and ranked 643rd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Bionano Genomics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Bionano Genomics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Bionano Genomics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bionano Genomics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Bionano Genomics has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.93% of the float of Bionano Genomics has been sold short.

Short Interest Ratio / Days to Cover

Bionano Genomics has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bionano Genomics has recently decreased by 19.37%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bionano Genomics does not currently pay a dividend.

Dividend Growth

Bionano Genomics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.93% of the float of Bionano Genomics has been sold short.

Short Interest Ratio / Days to Cover

Bionano Genomics has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bionano Genomics has recently decreased by 19.37%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.73

News Sentiment

Bionano Genomics has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Bionano Genomics this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for BNGO on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bionano Genomics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.90% of the stock of Bionano Genomics is held by insiders.

Percentage Held by Institutions

Only 11.35% of the stock of Bionano Genomics is held by institutions.

BNGO Stock Analysis - Frequently Asked Questions

How have BNGO shares performed this year?

Bionano Genomics' stock was trading at $17.3040 at the start of the year. Since then, BNGO stock has decreased by 76.9% and is now trading at $4.00.

How were Bionano Genomics' earnings last quarter?

Bionano Genomics, Inc. (NASDAQ:BNGO) released its quarterly earnings data on Thursday, August, 14th. The company reported ($1.99) earnings per share for the quarter, beating analysts' consensus estimates of ($2.69) by $0.70. The business earned $6.73 million during the quarter, compared to analysts' expectations of $6.90 million. Bionano Genomics had a negative trailing twelve-month return on equity of 129.41% and a negative net margin of 271.02%.
Read the conference call transcript.

When did Bionano Genomics' stock split?

Bionano Genomics shares reverse split on Monday, January 27th 2025.The 1-60 reverse split was announced on Wednesday, January 22nd 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

When did Bionano Genomics IPO?

Bionano Genomics (BNGO) raised $16 million in an initial public offering (IPO) on the week of August 20th 2018. The company issued 2,500,000 shares at a price of $6.00-$7.00 per share. Roth Capital Partners and Maxim Group acted as the underwriters for the IPO and LifeSci Capital was co-manager.

How do I buy shares of Bionano Genomics?

Shares of BNGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bionano Genomics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bionano Genomics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), Waste Connections (WCN), AU Optronics (AUOTY), American Water Works (AWK) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 8/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:BNGO
• CIK: 1411690
• Web: www.bionanogenomics.com
• Phone: (858) 888-7600
• Fax: N/A
• Employees: 300
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Bionano Genomics: $7.50
• High Price Target: $11.00
• Low Price Target: $4.00
• Potential Upside/Downside: +87.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($138.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$112.02 million
• Net Margins: -271.02%
• Pretax Margin: -270.87%
• Return on Equity: -129.41%
• Return on Assets: -72.25%

Debt

• Debt-to-Equity Ratio: 0.08
• Current Ratio: 1.76
• Quick Ratio: 1.34

Sales & Book Value

• Annual Sales: $27.43 million
• Price / Sales: 0.49
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.69 per share
• Price / Book: 0.41

Miscellaneous

• Outstanding Shares: 3,364,000
• Free Float: 3,334,000
• Market Cap: $13.46 million
• Optionable: Optionable
• Beta: 2.06